INTR
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
01/16/2026
Back to search
Official data from USPTO
INFLAZOME TARGETED THERAPIES FOR INFLAMMATORY DISEASES
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
38
Latest update
01/17/2026
Trademark type
Combined
Nice classes
1, 5, 9, 10
Filing date
02/03/2017
Registration date
10/30/2018
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
05/16/2025
Last transaction
01/17/2026
Responsible office
United States Patent and Trademark Office
Status code
709
Official register
Principal Register
Drawing code
3
Owner type
11
Owner location
IE
Examiner
STOIDES,KATHERINE
Law office
L10
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the wording "INFLAZOME TARGETED THERAPIES FOR INFLAMMATORY DISEASES" in stylized green blue lettering, depicted to the right of a hexagon figurative element in orange and green blue.
Holders and representatives
Holders
INFLAZOME LIMITED
Representatives
JANET G RICCIUTI JANET GILBERT RICCIUTI, PC
Technical classification
Nice Classes
Class 1Class 5Class 9Class 10
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Chemical reagents for scientific use; chemical diagnostic reagent for industrial use
Class 5
Diagnostic preparations for medical use; reagents for use in diagnostic tests for medical purposes; medical preparations and articles
Class 9
Diagnostic apparatus not for medical purposes; computer software in the field of diagnosis; laboratory apparatus and instruments
Class 10
Apparatus and instruments for medical diagnosis
Publications
History of USPTO decisions and trademark events.
38 publications found
C71T
CANCELLED SECTION 71
05/16/2025
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
10/30/2023
NREP
NEW REPRESENTATIVE AT IB RECEIVED
11/14/2019
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
02/22/2019
FICS
FINAL DISPOSITION NOTICE SENT TO IB
02/06/2019
FIMP
FINAL DISPOSITION PROCESSED
02/05/2019
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
01/30/2019
R.PR
REGISTERED-PRINCIPAL REGISTER
10/30/2018
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
08/14/2018
PUBO
PUBLISHED FOR OPPOSITION
08/14/2018
GPNX
NOTIFICATION PROCESSED BY IB
08/11/2018
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
07/25/2018
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
07/25/2018
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
07/25/2018
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
07/09/2018
XAEC
EXAMINER'S AMENDMENT ENTERED
07/09/2018
ALIE
ASSIGNED TO LIE
07/09/2018
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
07/07/2018
GNEA
EXAMINERS AMENDMENT E-MAILED
07/07/2018
CNEA
EXAMINERS AMENDMENT -WRITTEN
07/07/2018
GPRN
NOTIFICATION OF PRIORITY ACTION E-MAILED
01/13/2018
GPRA
PRIORITY ACTION E-MAILED
01/13/2018
CPRA
PRIORITY ACTION WRITTEN
01/13/2018
DMCC
DATA MODIFICATION COMPLETED
12/30/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/21/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/21/2017
ALIE
ASSIGNED TO LIE
12/19/2017
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/12/2017
RFNT
REFUSAL PROCESSED BY IB
07/08/2017
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
06/18/2017
RFRR
REFUSAL PROCESSED BY MPU
06/17/2017
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
06/11/2017
CNRT
NON-FINAL ACTION WRITTEN
06/10/2017
MAFR
APPLICATION FILING RECEIPT MAILED
06/09/2017
DOCK
ASSIGNED TO EXAMINER
06/06/2017
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/05/2017
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
06/01/2017
Continuous trademark protection
Get notified about every new filing that threatens INFLAZOME TARGETED THERAPIES FOR INFLAMMATORY DISEASES or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.